106 results on '"Skřičková J"'
Search Results
2. Design and monitoring of the Czech population pilot programme for lung cancer early detection
3. Pulmonary Infiltrate Etiology in Leukemic Patients with Fever
4. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients
5. PEMETREXED IN THE SECOND LINE CHEMOTHERAPY OF NON SMALL CELL LUNG CANCER. A MULTICENTRE PROSPECTIVE ANALYSIS OF DATA FROM CLINICAL PRACTICE: 074
6. Program časného záchytu karcinomu plic.
7. Projekt „Časný záchyt chronické obstrukční plicní nemoci v rizikové populaci" -- jaké jsou průběžné výsledky?
8. HSD57 The Actionable Gaps of the Journey of Patients With Lung Cancer
9. EP1.04-21 Chronic Inflammation as Potential Predictive Factor of Nivolumab Therapy in Non-Small Cell Lung Cancer
10. P2.14-34 Tyrosine-Kinase Inhibitors (TKI) in First-Line Treatment of 470 Patients with Non-Small Cell Lung Cancer (NSCLC) from the Czech Republic
11. Cytokiny v kondenzátu vydechovaného vzduchu u asthma bronchiale a idiopatické plicní fibrózy.
12. Karcinom plic - dia gnostika a časný záchyt.
13. Překvapivý nález v kostní dřeni: co za ním je?
14. 1405P Survival of patients with non-small cell lung cancer and exon 20 insertion mutation from the Czech Republic
15. 483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
16. Karcinom plic – aktuální možnosti léčby.
17. Exogenous lipoid pneumonia caused by chronic improper use of baby body oil in adult patient
18. P2.03-023 Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic
19. WS11.5 New approach for CF diagnosis based on chloride/potassium ion ratios analyzed in non-invasively obtained skin wipe sweat samples
20. Group of patients with NSCLC treated with erlotinib in the Czech Republic longer than 12 months
21. Pro-gastrin-releasing peptide (ProGRP)—Sensitive marker and prognostic factor in patients with small cell lung cancer
22. Activating mutations in the epidermal growth factor receptor gene in non-small cell lung cancer fixed tissue: Analysis and one center experience
23. Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung cancer (NSCLC): A prospective multicentre study of feasibility, tolerability and short time survival
24. Erlotinib treatment results in patients with advanced non-small-cell lung cancer (NSCLC)—Influence of clinical predictors
25. Eclampsia as a cause of secondary non-obstructive central sleep hypoventilation.
26. Screening rizika malnutrice versus ukazatelé nutričního stavu a systémové zánětlivé odpovědi u pacientů s nově dia gnostikovaným karcinomem plic.
27. Capillary Electrophoretic Analysis of Exhaled Breath Condensate in the Diagnosis of Gastroesophageal Reflux Disease
28. Bronchoalveolar lavage in the diagnosis of pneumocystis carinii pneumonia in patients with hematologic malignancies
29. Diagnostika, prognostické faktory a léčba sarkoidózy -- retrospektivní analýza.
30. Skrytá cystická fibróza u nemocného se sarkoidózou.
31. 9133 Analysis of treatment effects of erlotinib in non small cell lung cancer patients
32. 59P MARKERS OF PROLIFERATION ACTIVITY IN NON-SMALL CELL LUNG CANCER
33. 6 Chemotherapy with paclitaxel, carboplatin and concurrent radiotherapy for advanced non small cell lung cancer
34. P-975 The results of the treatment with gefitinib (Iressa) in 89 patientswith advanced non-small cell lung cancer (NSCLC)
35. P-921 The 5-years results of the surgical treatment in patients with non-small cell lung cancer (NSCLC): An analysis of 540 patients
36. Population pilot program for early detection of lung cancer in the czech republic,Populační pilotní program časného záchytu karcinomu plic v české republice
37. TULUNG registry | Klinický registr TULUNG
38. Information on the TARCEVA clinical registry | Informace o klinickém Registru TARCEVA
39. Bronchoscopy in the Czech Republic in 2012
40. The role of bronchial artery embolization in the treatment of hemoptysis,Postavení embolizace bronchiální tepny v terapii klinicky významné hemoptýzy
41. Towards a regional network of respiratory medicine
42. Concept of pneumology and phthiseology | Koncepce oboru pneumologie a ftizeologie (PNE) Verze z 12. 12. 2012
43. TARCEVA clinical registry | Klinický registr TARCEVA
44. Solitary lung lesions on CT scans in the at-risk population. Draft Guidelines for Management of Lung Lesions in the At-Risk Population,Solitární plicní ložiska na CT vyšetření u rizikové populace: Návrh Doporučeného postupu managementu plicních ložisek u rizikové populace
45. Continuation maintenance therapy with pemetrexed in patients with non-small-cell lung cancer in the Czech Republic | Pokračovací udržovací léčba pemetrexedemu u nemocných s nemalobuněčným karcinomem plic v České Republice
46. The role of bronchial artery embolization in the treatment of hemoptysis | Postavení embolizace bronchiální tepny v terapii klinicky významné hemoptýzy
47. Results of gefitinib effectiveness and toxicity in non-small cell lung cancer patients within the extended access program in the Czech Republic.,Výsledky klinického hodnoceni úcinnosti a toxicity gefitinibu v rámci programu časného pf̌ ístupu u nemalobuněčněho karcinomu plic v České republice
48. New options of expensive pneumo-oncological therapy for advanced non-small-cell lung carcinoma (NSCLC) in the first line based on morphological and molecular genetic diagnosis in the Czech Republic | Nové možnosti nákladné pneumoonkologické lécby pokrocilého nemalobunecného karcinomu plic (NSCLC) v první linii dle morfologické a molekulárne genetické diagnostiky v Ceské republice
49. Efficiency and safety of pemetrexed and cisplatin therapy in the adenocarcinoma and large cell cancer tjrpes of advanced non-small cell lung cancer (NSCLC) | Účinnost a bezpečnost léčby pemetrexedem a cisplatinou u pokročilého nemalobuněčného karcinomu plic (NSCLC) typu adenokarcinomu a velkobuněčného karcinomu
50. 771 Paclitaxel and carboplatin as adjuvant treatment in high-risk patients with operable non-small cell lung cancer (NSCLC): A feasibility study conducted by the hellenic cooperative oncology group (HeCOG)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.